Skip to main content
DC 7528Genitourinary System

Secondary Conditions for Malignant Neoplasms of the Genitourinary System

6 conditions have documented medical links to Malignant Neoplasms of the Genitourinary System. These may qualify as secondary service-connected disabilities if you can establish a medical nexus.

Evidence Strength:STRONGMODERATEEMERGING
STRONG

Medical Rationale

Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common and clinically significant dose-limiting toxicities of cancer chemotherapy, affecting 30–68% of patients depending on the agent, dose, and cumulative exposure. Neurotoxic chemotherapy agents (platinum compounds: cisplatin, oxaliplatin; taxanes: paclitaxel, docetaxel; vinca alkaloids: vincristine; proteasome inhibitors: bortezomib; thalidomide) damage peripheral sensory neurons through distinct but overlapping mechanisms: mitochondrial dysfunction and ATP depletion in dorsal root ganglion neurons; axonal microtubule disruption impairing axonal transport; DNA damage to DRG nuclei; oxidative stress and endoplasmic reticulum stress; and immune-mediated neurotoxicity. CIPN manifests as distal symmetric sensory neuropathy with painful paresthesias, numbness, and balance impairment, often persisting long after chemotherapy completion.

Key Studies

Cavaletti G & Marmiroli P (2010) Nat Rev Neurol (CIPN mechanisms); Seretny M et al. (2014) Pain (CIPN prevalence meta-analysis); Staff NP et al. (2017) Nat Rev Neurol; Flatters SJL et al. (2017) Handb Clin Neurol.

Filing Tips

Oncology records documenting chemotherapy regimen (drug, dose, number of cycles), correlated with neuropathy onset timing. Nerve conduction study (NCS) documenting sensory-predominant polyneuropathy — typically with reduced or absent sural nerve sensory nerve action potential amplitudes (SNAP). Neurology records documenting CIPN diagnosis and treatment (duloxetine, gabapentin, physical therapy). Rate CIPN per affected extremity under the peripheral nerve schedule. Each limb rated separately adds value to the combined disability calculation.

STRONG

Medical Rationale

Cancer-related fatigue (CRF) is the most prevalent, persistent, and distressing symptom experienced by cancer survivors, distinct from ordinary tiredness in its severity, duration, and disproportionate relationship to activity. CRF is rated separately from any underlying psychiatric condition. Pathophysiological mechanisms include: sustained pro-inflammatory cytokine elevation (IL-6, TNF-alpha, IL-1beta) from tumor presence and treatment-related immune activation causing neuroimmunological fatigue; HPA axis dysregulation with cortisol rhythm disruption; anemia from chemotherapy-induced bone marrow suppression; cancer- and treatment-induced hypothyroidism or adrenal insufficiency; deconditioning from activity restriction; and direct central neurotoxic effects of chemotherapy. CRF persists years to decades after cancer treatment in a significant subset, representing a chronic functional impairment rateable under VA disability schedules.

Key Studies

Bower JE (2014) J Clin Oncol (CRF mechanisms); Bower JE et al. (2011) Brain Behav Immun (inflammatory biology of CRF); Dantzer R et al. (2012) Nat Rev Immunol (cytokine-induced sickness and depression); Bower JE & Lamkin DM (2013) Nat Rev Cancer.

Filing Tips

Oncology records documenting cancer diagnosis, treatment, and fatigue complaints. Validated fatigue assessment scales from clinical records (FACIT-Fatigue, Brief Fatigue Inventory). Endocrinology records ruling out treatable secondary causes (hypothyroidism, adrenal insufficiency). Hematology records documenting anemia if chemotherapy-related. CRF is typically rated as part of the cancer rating or as a secondary condition under the closest analogous diagnostic code. A functional capacity evaluation or occupational therapy records documenting activity limitation from fatigue supports the rating.

STRONG

Medical Rationale

Erectile dysfunction is among the most common and severe quality-of-life consequences of prostate cancer treatment, affecting 60–90% of men treated with radical prostatectomy and 25–60% treated with radiation therapy. Radical prostatectomy — even nerve-sparing — damages the cavernous nerves (branches of the pelvic splanchnic nerves) that course along the posterolateral prostate and mediate reflexogenic erection. Radiation therapy causes progressive obliterative endarteritis of the cavernous arteries and radiation fibrosis of the corpus cavernosum and penile neurovascular bundle. Androgen deprivation therapy (ADT) suppresses testosterone to castrate levels, abolishing both libido and erectile function via hypothalamic-pituitary-gonadal axis suppression. ED following prostate cancer treatment is expected, universal, and a medically established direct complication requiring no nexus letter in many cases.

Key Studies

Sanda MG et al. (2008) N Engl J Med (prostate cancer treatment outcomes); Resnick MJ et al. (2013) N Engl J Med (RP vs radiation ED long-term); Capogrosso P et al. (2019) Eur Urol (ED after prostate cancer treatment); Kim ED et al. (2001) Urology (nerve-sparing RP and ED).

Filing Tips

This is one of the strongest and most straightforward secondary cancer-treatment claims. Prostate cancer treatment records (operative report for RP, radiation treatment plan/dosimetry records, ADT prescription records) directly establish the treatment nexus. Urology records documenting post-treatment ED evaluation and treatment. File for SMC-K separately. A nexus letter is generally easy to obtain and may not even be required given the well-established causal relationship documented in medical literature and treatment informed-consent documents.

STRONG

Medical Rationale

Depression and anxiety are among the most prevalent and undertreated complications of cancer, with systematic reviews documenting major depression in 8–24% and clinically significant anxiety in 10–30% of cancer patients. Cancer causes psychiatric disorders through multiple mechanisms: (1) direct neurobiological effects — pro-inflammatory cytokines (IL-1β, IL-6, TNF-alpha) released by tumors and activated immune cells cross the blood-brain barrier and cause cytokine-induced depression ("sickness behavior" mediated by indoleamine 2,3-dioxygenase activation depleting serotonin precursor tryptophan); (2) hypothalamic-pituitary-adrenal axis dysregulation from chronic tumor-related stress; (3) cancer treatment effects — chemotherapy-induced direct neurotoxicity, steroid-induced psychiatric effects, hormonal manipulation; and (4) profound psychosocial stressors from diagnosis, prognosis uncertainty, functional decline, and existential threat.

Key Studies

Massie MJ (2004) J Natl Cancer Inst (depression in cancer meta-analysis); Mitchell AJ et al. (2011) Lancet Oncol (psychiatric disorders in cancer); Spiegel D & Giese-Davis J (2003) Biol Psychiatry (depression and cancer biology); Walker J et al. (2014) Lancet (depression in cancer).

Filing Tips

Psychiatric records documenting depression or anxiety disorder onset or significant worsening following cancer diagnosis or during/after treatment. Oncology records establishing the cancer service connection. A nexus letter from your oncologist and/or psychiatrist is important for the secondary claim. Many veterans with Agent Orange-related cancers (prostate, bladder, non-Hodgkin lymphoma) can file secondary depression claims that add substantial rating value. The causal connection between cancer and depression is so well established that the VA should grant the secondary claim upon a well-supported nexus letter.

STRONG

Medical Rationale

Urinary incontinence is a direct and expected complication of prostate cancer surgical and radiation treatment. Radical prostatectomy removes the prostate, disrupting the external urethral sphincter mechanism, and the neurovascular bundles controlling sphincter function. Post-prostatectomy stress urinary incontinence (leakage with physical exertion, coughing, or straining) results from impaired external sphincter function when the intrinsic sphincter mechanism provided by the prostatic urethra is removed. Radiation therapy causes radiation cystitis, bladder fibrosis, reduced bladder capacity, detrusor overactivity, and radiation-induced urethral stenosis — producing urgency urinary incontinence and/or overflow incontinence from outflow obstruction. The Prostate Cancer Outcomes Study documented clinically significant urinary incontinence in 17% of men 2 years after RP and 6% after radiation, with much higher rates of any urinary bother.

Key Studies

Sanda MG et al. (2008) N Engl J Med (PCOS outcomes); Potosky AL et al. (2000) JNCI (incontinence after RP and radiation); Stanford JL et al. (2000) JAMA; Walsh PC et al. (2000) J Urol (nerve-sparing and continence).

Filing Tips

Urology records documenting urinary incontinence type (stress, urgency, or mixed), degree of pad use per day, urodynamic study results, and treatment (pelvic floor therapy, alpha-blockers, anticholinergics, sphincter prosthesis). Incontinence rated under the genitourinary schedule based on frequency and pad requirement. Stress incontinence requiring absorbent products rated at 20%; requiring use of absorbent products, 40%; requiring AMS 800 artificial sphincter, 40–100%. This is a direct complication requiring minimal nexus documentation beyond treatment records.

STRONG

Medical Rationale

Radical prostatectomy and pelvic radiation for prostate cancer produce urinary incontinence through distinct but well-understood mechanisms. Prostatectomy disrupts the internal urethral sphincter and damages the rhabdosphincter (external sphincter), which must then assume sole continence function. Even with nerve-sparing techniques, 5-20% of men have persistent stress urinary incontinence at 1 year. Radiation therapy causes progressive radiation cystitis — fibrosis of the detrusor muscle and urothelial atrophy — producing both storage symptoms (urgency, frequency) and overflow incontinence from poor detrusor compliance. Radiation fibrosis is progressive and may worsen for years after treatment completion. Combined modality treatment (surgery plus adjuvant radiation) carries the highest incontinence risk.

Key Studies

Sanda MG et al. (2008) N Engl J Med (quality of life after prostate cancer treatment — urinary outcomes); Ficarra V et al. (2012) Eur Urol (urinary continence after radical prostatectomy — systematic review).

Filing Tips

Urology records documenting urinary incontinence onset after prostatectomy or radiation. Urodynamic studies quantifying sphincter insufficiency and detrusor dysfunction. Pad usage documentation (number per day). Urology nexus letter — though for post-prostatectomy incontinence, the causal link is typically self-evident and may not require an IMO. File under DC 7542 (neurogenic bladder) or under voiding dysfunction criteria. The absorbent materials requirement (pad usage) determines the rating percentage: 2+ pads per day can warrant 40-60% rating for voiding dysfunction.

← Back to Malignant Neoplasms of the Genitourinary System rating criteria

Find All Secondary Conditions for Your Situation

AIDEN can analyze your complete medical history and identify secondary conditions specific to your case, including connections that may not appear in standard databases.

Discover Your Secondary Conditions